ResearcherUniversity of CopenhagenActive in the last 2 years
Estrid Vilma Solyom Høgdall
Matched on ORCID iD 0000-0003-4689-5658; OpenAlex author ID A5030595220. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2023: 2 papers · 2024: none · 2025: 2 papers
Papers 4
- A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). Co-author DOI 10.1016/j.iotech.2025.101054↗
- Paired Comparison of Whole Genome Sequencing and Comprehensive Targeted Sequencing of Pancreatic Cancer Tissue. Last author DOI 10.21873/anticanres.17447↗
- Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Co-author DOI 10.1016/j.ejca.2022.11.035↗
- Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15143677↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Inna Markovna Chen · 3 shared papers, 2023–2025 · strength 0.73
- Paper Paired Comparison of Whole Genome Sequencing and Comprehensive Targeted Sequencing of Pancreatic Cancer Tissue. DOI 10.21873/anticanres.17447↗
- Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
- Paper Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
- Susann Theile · 2 shared papers, 2023–2025 · strength 0.41
- Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
- Paper Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
- Dorte Lisbet Nielsen · 2 shared papers, 2023–2025 · strength 0.41
- Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
- Paper Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
- Julia Sidenius Johansen · 2 shared papers, 2023–2025 · strength 0.41
- Paper A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancrea… DOI 10.1016/j.iotech.2025.101054↗
- Paper Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
- Thea Amalie Hvidtfeldt · 1 shared paper, 2025 · strength 0.33
- Hanne Grossjohann · 1 shared paper, 2023 · strength 0.15
- Peter Vilmann · 1 shared paper, 2023 · strength 0.15
- Simon Ezban Grützmeier · 1 shared paper, 2023 · strength 0.15
- Pia Helene Klausen · 1 shared paper, 2023 · strength 0.15
- Carsten Palnæs Hansen · 1 shared paper, 2023 · strength 0.15
- Bojan Kovacevic · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.